Font Size, 'Look-Alikes' And Costs Are Top Concerns In Australian Drug Labeling Review
This article was originally published in SRA
As part of a drive to get pharmaceutical companies to put clearer and more comprehensive information on their drug labels, Australia's regulatory body, the Therapeutic Goods Administration, is asking stakeholders to comment on its newly updated labeling rules, which among other things would impose a minimum font size for active substance names and require more substances to be listed on the label1.
You may also be interested in...
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.